Aurobindo Subsidiary TheraNym Signs Deal with MSD for Biologics Manufacturing

Aurobindo Pharma Limited made a significant announcement regarding its subsidiary, TheraNym Biologics Private Limited, on May 31, 2024. TheraNym has entered into a Master Service Agreement (MSA) with Merck Sharpe & Dohme Singapore Trading (MSD). This agreement marks a pivotal moment in the company's trajectory and signifies a major step towards expanding its biologics manufacturing capabilities. TheraNym plans to invest approximately Rs. 1,000 crore in establishing a new facility as part of this agreement.

This development is in line with Aurobindo Pharma's previous statements regarding its intentions to bolster its biologics manufacturing infrastructure and explore opportunities in contract manufacturing operations (CMO) for biologicals.

Per the terms of the master service agreement, TheraNym will construct a state-of-the-art manufacturing facility dedicated to producing products for MSD. The facility will be situated at Borapatla (V), Hathnoora Mandal, in the Medak District of Telangana.

The agreement is expected to be mutually beneficial for both Aurobindo Pharma and MSD. For Aurobindo Pharma, it represents an entry into the contract manufacturing market for biologicals, opening up new avenues for growth and expansion. For MSD, it provides access to a reliable and efficient manufacturing partner, facilitating the production of essential products.

Overall, this collaboration underscores Aurobindo Pharma's commitment to advancing its presence in the biologics sector and reinforces its position as a key player in the pharmaceutical industry.

BS